Wedbush reissued their outperform rating on shares of Nightstar Therapeutics (NASDAQ:NITE) in a research note published on Thursday morning. The firm currently has a $31.00 price target on the stock. Wedbush also issued estimates for Nightstar Therapeutics’ FY2022 earnings at $0.83 EPS.
A number of other equities analysts have also recently issued reports on NITE. Mizuho restated a buy rating and issued a $20.00 price objective on shares of Nightstar Therapeutics in a research note on Thursday. Chardan Capital began coverage on shares of Nightstar Therapeutics in a report on Wednesday, January 3rd. They issued a buy rating and a $40.00 target price on the stock. One research analyst has rated the stock with a sell rating and six have assigned a buy rating to the company. The company presently has an average rating of Buy and a consensus target price of $28.50.
Shares of NITE stock opened at $11.70 on Thursday. Nightstar Therapeutics has a 52-week low of $10.01 and a 52-week high of $24.93. The firm has a market capitalization of $328.77 and a PE ratio of -7.18.
TRADEMARK VIOLATION WARNING: “Nightstar Therapeutics’ (NITE) Outperform Rating Reaffirmed at Wedbush” was originally posted by Ticker Report and is owned by of Ticker Report. If you are reading this report on another site, it was illegally copied and reposted in violation of United States & international copyright laws. The original version of this report can be viewed at https://www.tickerreport.com/banking-finance/3341248/nightstar-therapeutics-nite-outperform-rating-reaffirmed-at-wedbush.html.
Nightstar Therapeutics Company Profile
Nightstar Therapeutics plc, a clinical-stage gene therapy company, focuses on developing and commercializing novel one-time treatments for patients suffering from rare inherited retinal diseases in the United Kingdom. The company's lead product candidate includes NSR-REP1, a candidate that has completed Phase 1/2 clinical trial for the treatment of patients with choroideremia.
Receive News & Ratings for Nightstar Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nightstar Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.